Advertisement

Incidence and long-term prognosis of papillary renal cell carcinoma

  • A. J. Schrader
  • S. Rauer-Bruening
  • P. J. Olbert
  • A. Hegele
  • J. Rustemeier
  • N. Timmesfeld
  • Z. Varga
  • R. Hofmann
Original Paper

Abstract

Objectives

Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non-clear-cell kidney cancer. In this study, we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).

Methods

We evaluated 744 patients who had undergone renal surgery for RCC between 1990 and 2005. The mean follow-up was 5.6 years, the patients being followed-up until December 2007.

Results

Both groups, pRCC and ccRCC, were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis. The percentage of male patients was higher in pRCC than in ccRCC (73.8 vs. 60.3%, p = 0.006). Even though patients with pRCC presented more often with smaller (p = 0.039) and low-grade tumours (p = 0.006), there was no statistically significant difference in tumour recurrence or tumour related death. Kaplan–Meier curves revealed no differences regarding tumour specific survival between pRCC and ccRCC (p = 0.94; 5-year survival 78 vs. 77%).

Conclusions

Even though pRCC and ccRCC differ significantly in many aspects including histology and genetic alterations, their long term prognosis is comparable. As we could not confirm a favourable clinical course for pRCC in general, standardised aftercare programmes and—if necessary—systemic treatment, especially in the era of novel targeted drugs, are also needed for this common RCC subtype.

Keywords

Papillary Conventional Clear-cell Kidney cancer Specific characteristics Prognosis 

References

  1. Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, Menon M (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26:281–291. doi: 10.1097/00000478-200203000-00001 PubMedCrossRefGoogle Scholar
  2. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612–624. doi: 10.1097/00000478-200305000-00005 PubMedCrossRefGoogle Scholar
  3. Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537–544PubMedGoogle Scholar
  4. Delahunt B, Bethwaite PB, Nacey JN (2007) Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology 39:459–465. doi: 10.1080/00313020701570061 PubMedCrossRefGoogle Scholar
  5. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV (2005) Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol 48:593–600. doi: 10.1016/j.eururo.2005.04.016 PubMedCrossRefGoogle Scholar
  6. Herrmann E, Brinkmann OA, Bode ME, Bierer S, Kopke T, Bogemann M, Hertle L, Wulfing C (2007) Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil. Eur Urol 51:1625–1631. doi: 10.1016/j.eururo.2006.11.003 PubMedCrossRefGoogle Scholar
  7. Kim H, Cho NH, Kim DS, Kwon YM, Kim EK, Rha SH, Park YW, Shim JW, Lee SS, Lee SN, Lee J, Lee JS, Lee TJ, Jung SJ, Jung SH, Chung JH, Cho HY, Joo HJ, Choi YJ, Choi C, Han WS, Hur B, Ro JY (2004) Renal cell carcinoma in South Korea: a multicenter study. Hum Pathol 35:1556–1563. doi: 10.1016/j.humpath.2004.06.011 PubMedCrossRefGoogle Scholar
  8. Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Bohm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ (2007) Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 177:2081–2086. doi: 10.1016/j.juro.2007.01.122 PubMedCrossRefGoogle Scholar
  9. Krambeck A, Iwaszko M, Leibovich B, Cheville J, Frank I, Blute M (2008) Long-term outcome of multiple ipsilateral renal tumours found at the time of planned nephron-sparing surgery. BJU Int 101:1375–1379. doi: 10.1111/j.1464-410X.2008.07588.x PubMedCrossRefGoogle Scholar
  10. Lin ZH, Han EM, Lee ES, Kim CW, Kim HK, Kim I, Kim YS (2004) A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod Pathol 17:611–616. doi: 10.1038/modpathol.3800108 PubMedCrossRefGoogle Scholar
  11. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163–2172. doi: 10.1097/01.ju.0000096060.92397.ed PubMedCrossRefGoogle Scholar
  12. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L (2004) Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10:6282S–6289S. doi: 10.1158/1078-0432.CCR-050013 PubMedCrossRefGoogle Scholar
  13. Ljungberg B, Alamdari FI, Stenling R, Roos G (1999) Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 36:565–569. doi: 10.1159/000020049 PubMedCrossRefGoogle Scholar
  14. Mancilla-Jimenez R, Stanley RJ, Blath RA (1976) Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 38:2469–2480 10.1002/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-RPubMedCrossRefGoogle Scholar
  15. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG (2008) Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 112:1480–1488. doi: 10.1002/cncr.23322 PubMedCrossRefGoogle Scholar
  16. Mejean A, Hopirtean V, Bazin JP, Larousserie F, Benoit H, Chretien Y, Thiounn N, Dufour B (2003) Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 170:764–767. doi: 10.1097/01.ju.0000081122.57148.ec PubMedCrossRefGoogle Scholar
  17. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89:604–614 10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-QPubMedCrossRefGoogle Scholar
  18. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376–2381. doi: 10.1200/JCO.2002.11.123 PubMedCrossRefGoogle Scholar
  19. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23:2763–2771. doi: 10.1200/JCO.2005.07.055 PubMedCrossRefGoogle Scholar
  20. Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, Debre B, Amsellem-Ouazana D (2007) Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 69:230–235. doi: 10.1016/j.urology.2006.09.052 PubMedCrossRefGoogle Scholar
  21. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, Bacik J, Motzer RJ (2006) Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 107:2617–2621. doi: 10.1002/cncr.22340 PubMedCrossRefGoogle Scholar
  22. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73. doi: 10.1038/ng0597-68 PubMedCrossRefGoogle Scholar
  23. Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R (2006a) Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol 132:137–149. doi: 10.1007/s00432-005-0058-4 PubMedCrossRefGoogle Scholar
  24. Schrader AJ, Varga Z, Pfoertner S, Goelden U, Buer J, Hofmann R (2006b) Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer. BJU Int 97:461–465. doi: 10.1111/j.1464-410X.2006.05873.x PubMedCrossRefGoogle Scholar
  25. Schrader AJ, Olbert PJ, Hegele A, Varga Z, Hofmann R (2008) Metastatic non-clear cell renal cell carcinoma: current therapeutic options. BJU Int 30:1343–1345. doi: 10.1111/j.1464-410X.2008.07462.x CrossRefGoogle Scholar
  26. Steiner T, Roigas J, Kirchner H, Doehn C, Heynemann H, Siebels M, Loening S, Jocham D, Fornara P, Rohde D, Stieff C (2006) Clinical course of patients with metastatic papillary renal cell carcinoma. J Clin Oncol 24 (Abstract 14591)Google Scholar
  27. Storkel S, Eble JN, Adlakha K, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K (1997) Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:987–989 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2PubMedCrossRefGoogle Scholar
  28. Sweeney P, El-Naggar AK, Lin SH, Pisters LL (2002) Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 168:51–55. doi: 10.1016/S0022-5347(05)64830-6 PubMedCrossRefGoogle Scholar
  29. Wunderlich H, Schlichter A, Zermann D, Reichelt O, Kosmehl H, Schubert J (1999) Multifocality in renal cell carcinoma: a bilateral event? Urol Int 63:160–163. doi: 10.1159/000030439 PubMedCrossRefGoogle Scholar
  30. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT (2005) A molecular classification of papillary renal cell carcinoma. Cancer Res 65:5628–5637. doi: 10.1158/0008-5472.CAN-05-0533 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • A. J. Schrader
    • 1
  • S. Rauer-Bruening
    • 1
  • P. J. Olbert
    • 1
  • A. Hegele
    • 1
  • J. Rustemeier
    • 1
  • N. Timmesfeld
    • 2
  • Z. Varga
    • 1
  • R. Hofmann
    • 1
  1. 1.Department of UrologyPhilipps-University Medical SchoolMarburgGermany
  2. 2.Institute for Medical Biometry and EpidemiologyPhilipps-University Medical SchoolMarburgGermany

Personalised recommendations